Androgen receptor antagonist 1 is an orally available full androgen receptor ( AR ) antagonist with an IC 50 of 59 nM Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively . In Vitro Androgen receptor antagonist 1 (Compound 26; 1 nM-100 μM) shows significant cell growth inhibition effects for LNCaP and LNAR cells but not DU145 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Prostate cancer (CaP) cells (LNCAP, LNAR, and DU145) Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM Incubation Time: 7 days Result: Antiproliferative effects of in LNCAP and LNAR cells. In Vivo Androgen receptor antagonist 1 (Compound 26; 100 mg/kg once a day for 5 weeks) demonstrates excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male athymic nude mice with LNCaP xenograft model of CRPC Dosage: 100 mg/kg Administration: Orally once a day for 5 weeks Result: Demonstrated outstanding efficacy in inhibiting tumor growth. At the given doses (100 mg/kg once a day) nearly completely suppressed tumor growth (by 90 %) and the PSA levels (78%) after 5 weeks, with no detectable body weight loss for the period of time when animals were treated. Form:Solid IC50& Target:IC50: 59 nM (androgen receptor)